44 completed, 7 recruiting, 5 unknown, 3 terminated. 64 Phase 2, 9 Phase 1, 6 Phase 3.
Follow Dengue: new trials by email Literature Review of Dengue trials Research Report on Dengue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emetine for Viral Outbreaks (a.k.a. EVOLVE Antiviral Initiative) Emetine Hydrochloride 6mg, Placebo, Emetine Hydrochloride 12mg - Dengue | Phase 2 / Phase 3 | Recruiting | Johns Hopkins University | 600 | 2026-09-01 | 2026-10-13 |
| Adaptive Dengue Antiviral Platform Trial Molnupiravir 400 mg, VIS513 (a monoclonal antibody), Remdesivir 100mg - Dengue, Antiviral Drugs | Phase 2 | Recruiting | Oxford University Clinical Research Unit, Vietnam | 500 | 2026-04-20 | 2026-09-28 |
| A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2) CP-COV03, Placebo - Dengue | Phase 2 / Phase 3 | Recruiting | Hyundai Bioscience Co., Ltd. | 210 | 2026-04-09 | 2026-07-10 |
| Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2) Resomelagon, Placebo, Standard Treatment - Dengue Fever | Phase 2 | Recruiting | Federal University of Minas Gerais | 120 | 2026-03-20 | 2026-09-15 |
| To Assess the Efficacy of Carica Papaya Leaf Extract in Improving Platelet Counts Among Pediatric Patients With Dengue-associated Thrombocytopenia Carica Papaya Leaf Extract Group, standard treatment - Dengue Fever, Papaya Leaf Extract | Phase 2 | Enrolling by invitation | Ziauddin Hospital | 100 | 2025-10-01 | 2025-09-15 |
| Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients Montelukast, Montelukast Placebo - Dengue, Montelukast | Phase 2 / Phase 3 | Recruiting | Phramongkutklao College of Medicine and Hospital | 82 | 2025-01-31 | 2025-05-29 |
| A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan TDV, Placebo - Dengue Fever | Phase 2 / Phase 3 | Completed | Takeda | 187 | 2025-01-31 | 2025-12-30 |
| A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection AV-1 100 mg, AV-1 300 mg, AV-1 900 mg - DENV-3 Controlled Human Infection Model | Phase 2 | Completed | AbViro LLC | 85 | 2025-01-07 | 2026-03-31 |
| Study to Examine the Effects of Oral Fenretinide ISLA101, Dengue 1 Live Virus Human Challenge (DENV-1-LVHC), Placebo - Dengue | Phase 2 | Completed | Island Pharmaceuticals | 15 | 2024-09-05 | 2025-10-24 |
| Effects of Carica Papaya Leaf Extract (CPLE) in the Outcome of Hospitalized Dengue Patients CPLE, Placebo - Dengue Fever | Phase 1 / Phase 2 | Completed | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 184 | 2024-06-01 | 2025-04-25 |
| Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE) Zanamivir, Placebo - Dengue Fever | Phase 2 | Recruiting | George Washington University | 74 | 2024-03-15 | 2026-07-29 |
| A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever EYU688, Placebo - Dengue | Phase 2 | Recruiting | Novartis Pharmaceuticals | 108 | 2024-02-20 | 2026-11-10 |
| Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome Arm-2 : 2,00,000 IU Vitamin D3 oral solution , Arm-3: 4,00,000 IU Vitamin D3 oral solution - Dengue Fever | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 120 | 2023-06-01 | 2023-10-06 |
| A Study of JNJ-64281802 for the Prevention of Dengue Infection JNJ-64281802, Placebo - Dengue | Phase 2 | Terminated | Janssen Research & Development, LLC | 1595 | 2023-02-22 | 2025-07-31 |
| Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002) V181, Butantan - DV - Dengue | Phase 2 | Completed | Butantan Institute | 1364 | 2023-02-15 | 2025-11-18 |
| Anakinra in Dengue With Hyperinflammation ( AnaDen ) Placebo, Anakinra - Dengue, Dengue With Warning Signs | Phase 2 | Active not recruiting | Oxford University Clinical Research Unit, Vietnam | 160 | 2023-01-02 | 2026-01-06 |
| Study of AT-752 in Patients With Dengue Infection AT-752, Placebo - Dengue Fever | Phase 2 | Terminated | Atea Pharmaceuticals, Inc. | 21 | 2022-04-29 | 2024-03-05 |
| An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge Cohort 1 - Group 1 JNJ High Dose, Cohort 1 - Group 2 JNJ Medium Dose, Cohort 1 - Group 2 JNJ Low Dose - Dengue | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 56 | 2022-02-03 | 2026-11-04 |
| A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever JNJ-64281802, Placebo - Dengue | Phase 2 | Terminated | Janssen Research & Development, LLC | 5 | 2022-01-24 | 2024-03-01 |
| Dengue Controlled Human Infection Model in Dhaka, Bangladesh TV005, rDEN2Δ30-7169 attenuated virus strain - Dengue | Phase 2 | Active not recruiting | Beth Kirkpatrick | 192 | 2021-12-11 | 2024-07-17 |
Showing 20 of 64. Sign in to see all of them.
Severe Dengue (21) · Virus Diseases (3) · Hemorrhagic Fevers, Viral (2) · Acquired Immunodeficiency Syndrome (1) · Cytokine Release Syndrome (1) · Infections (1) · Macrophage Activation Syndrome (1) · Obesity (1) · Overweight (1) · Vector Borne Diseases (1) · Yellow Fever (1)
Arbovirus Infections (64) · Flaviviridae Infections (64) · Flavivirus Infections (64) · Mosquito-Borne Diseases (64) · RNA Virus Infections (64) · Infections (63) · Vector Borne Diseases (63) · Hemorrhagic Fevers, Viral (62) · Virus Diseases (61) · Immune System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Blood-Borne Infections (1) · Body Weight (1) · Communicable Diseases (1)
Sodium Chloride (6) · Vaccines (3) · ChimeriVax (2) · Dengue Vaccines (2) · Dosage Forms (2) · Ivermectin (2) · adacel (2) · celgosivir (2) · montelukast (2) · 23-valent pneumococcal capsular polysaccharide vaccine (1) · AT-752 (1) · Chickenpox Vaccine (1) · Chloroquine (1) · Cholecalciferol (1) · Emetine (1)
Sanofi Pasteur, a Sanofi Company (14) · U.S. Army Medical Research and Development Command (7) · Takeda (5) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Oxford University Clinical Research Unit, Vietnam (3) · Sanofi (3) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (2) · Butantan Institute (2) · Janssen Research & Development, LLC (2) · Mahidol University (2) · Phramongkutklao College of Medicine and Hospital (2) · Singapore General Hospital (2) · AbViro LLC (1) · Atea Pharmaceuticals, Inc. (1) · Beth Kirkpatrick (1)
Thailand (13) · United States (12) · Brazil (10) · Colombia (7) · Singapore (7) · Vietnam (7) · Philippines (6) · Malaysia (5) · Mexico (5) · Bangladesh (4) · Puerto Rico (4) · India (3) · Peru (3) · Taiwan (3) · Honduras (2)
Rashidul Haque, MD (2) · Veerachai Watanaveeradej, MD (2) · Worapong Nasomsong, MD (2) · Aileen Chang, MD (1) · Alberto Santiago-Cornier, MD (1) · Alexander R Precioso, MD, PhD (1) · Anna Durbin, MD (1) · Anna Quintero, MD (1) · Benedito AL Fonseca, PhD (1) · Bert Slade, MD (1)
PMID 40099800, PMID 42253092, PMID 32932330, PMID 39308445, PMID 39356094, PMID 16269927, PMID 18337339, PMID 21813857, PMID 21976579, PMID 22863660, PMID 22894958, PMID 22975340, PMID 23208878, PMID 23540847, PMID 23839107, PMID 24021313, PMID 24067553, PMID 24189367, PMID 24865677, PMID 24877997, PMID 25483647, PMID 26175027, PMID 26214039, PMID 26291554, PMID 26794905, PMID 27102820, PMID 27509020, PMID 28137799, PMID 28365225, PMID 29122463, PMID 29897841, PMID 30241510, PMID 30986790, PMID 31464558, PMID 31843269, PMID 32119591, PMID 32197107, PMID 32220283, PMID 32342848, PMID 32572472, PMID 33083561, PMID 33113295, PMID 33124646, PMID 33212067, PMID 33332778, PMID 33534885, PMID 33626291, PMID 33684559, PMID 33711074, PMID 33822015
2014 (4), 2018 (1)